European Journal of Cancer最新文献

{"title":"Predictors of Pathological Complete Response (pCR) and Early Recurrence in Younger Patients (<50 years) with Breast Cancer (BC) receiving Neoadjuvant Systemic Therapy (NAST)","authors":"B. Gwyther ,&nbsp;R. Boopathy ,&nbsp;R. Javed ,&nbsp;E. Papadimitraki ,&nbsp;B. Kirresh ,&nbsp;J. Islam ,&nbsp;A. Hallam ,&nbsp;D. Betal ,&nbsp;K. DeSouza","doi":"10.1016/j.ejca.2026.116351","DOIUrl":"10.1016/j.ejca.2026.116351","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116351"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147539273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinguishing true recurrence from second primary breast cancer by molecular clonality analysis","authors":"T. Snellen ,&nbsp;E. Lips ,&nbsp;L. Bosch ,&nbsp;T. Wiersma ,&nbsp;A. Scholten ,&nbsp;M. Noë ,&nbsp;M.J. Vrancken Peeters ,&nbsp;V. Dezentjé","doi":"10.1016/j.ejca.2026.116314","DOIUrl":"10.1016/j.ejca.2026.116314","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116314"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147537823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative circulating circRNA profiling in breast cancer: An unbiased microarray analysis shows no consistent systemic surgical signature","authors":"K. Alba ,&nbsp;C.M. Jonassen ,&nbsp;A. Abbas ,&nbsp;G. Alnæs ,&nbsp;A. Tahiri ,&nbsp;O.J. Hartmann-Johnsen MD","doi":"10.1016/j.ejca.2026.116296","DOIUrl":"10.1016/j.ejca.2026.116296","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116296"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147538004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can neoadjuvant chemotherapy jeopardize immediate pre-pectoral breast reconstruction? A single high-volume center experience","authors":"C. Rizzetto ,&nbsp;I. Rocco ,&nbsp;B. Gnocato ,&nbsp;F. Callegari ,&nbsp;A. Pozza ,&nbsp;M. Variolo ,&nbsp;F. Centanini ,&nbsp;F. Milardi ,&nbsp;G. Berna","doi":"10.1016/j.ejca.2026.116355","DOIUrl":"10.1016/j.ejca.2026.116355","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116355"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147544865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early integrated rehabilitation and the patient's gynecological problems, sexual functioning and sexual enjoyment six months and one year after the beginning of breast cancer treatment - A prospective study in 600 breast cancer patients","authors":"N. Besic ,&nbsp;M. Kurir ,&nbsp;Z. Mavric ,&nbsp;A. Mozetic ,&nbsp;A.C. Skufca Smrdel ,&nbsp;S. Borstnar ,&nbsp;I. Ratosa ,&nbsp;V. Hadzic ,&nbsp;L. Zadravec Zaletel ,&nbsp;N. Kovacevic","doi":"10.1016/j.ejca.2026.116368","DOIUrl":"10.1016/j.ejca.2026.116368","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116368"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147544921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer and communication: patient insights from Serbia","authors":"S. Bojanic ,&nbsp;M. Branković-Magić","doi":"10.1016/j.ejca.2026.116313","DOIUrl":"10.1016/j.ejca.2026.116313","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116313"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147547169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual function in young breast cancer survivors: Influence of treatment modalities in an observational study from Uruguay","authors":"N. Camejo ,&nbsp;C. Castillo ,&nbsp;S. Rosina ,&nbsp;M. Gianina ,&nbsp;M. Joaquin ,&nbsp;A. Dahiana ,&nbsp;G. Maria ,&nbsp;H. Guadalupe ,&nbsp;D. Carolina ,&nbsp;K. Gabriel","doi":"10.1016/j.ejca.2026.116359","DOIUrl":"10.1016/j.ejca.2026.116359","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116359"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147554134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An updated European organization for research and treatment of cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for merkel cell carcinoma (MCC)","authors":"Anna Szumera-Ciećkiewicz ,&nbsp;Piotr Donizy ,&nbsp;Thibault Kervarrec ,&nbsp;Witold Skrzyński ,&nbsp;Llucia Alos ,&nbsp;Natalia Castrejon-De-Anta ,&nbsp;Filippo Ugolini ,&nbsp;Jakub Mizera ,&nbsp;Daniela Mihic-Probst ,&nbsp;Martin G. Cook ,&nbsp;Bastian Schilling ,&nbsp;Piotr Rutkowski ,&nbsp;Alexander M.M. Eggermont ,&nbsp;Mario Mandalà ,&nbsp;Daniela Massi ,&nbsp;on behalf of EORTC Melanoma Group","doi":"10.1016/j.ejca.2026.116587","DOIUrl":"10.1016/j.ejca.2026.116587","url":null,"abstract":"<div><div>Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a high risk of regional lymph-node metastasis. Accurate pathological evaluation of sentinel lymph nodes (SLN) is therefore critical for staging and clinical management, yet current practices remain heterogeneous across centres. An expert panel within the European Organisation for Research and Treatment of Cancer (EORTC) reviewed available evidence and contemporary practice to develop updated consensus guidance for the pathological assessment of SLN in MCC. The recommendations address specimen handling, lymph-node sectioning strategies, tumour-burden definitions, standardized reporting elements, and a pragmatic approach to ancillary immunohistochemistry (IHC). The proposed protocol provides clear guidance on SLN processing and sectioning to optimize the detection of micrometastatic disease, together with an algorithmic IHC framework that prioritizes sensitive screening markers followed by confirmatory stains to ensure reliable identification of occult nodal involvement. Emphasis is placed on consistent documentation of tumour burden and pN classification to support reproducible reporting and informed clinical decision-making.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116587"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147270235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study","authors":"Lea Jessica Albrecht ,&nbsp;Jana Garnier ,&nbsp;Anne Zaremba ,&nbsp;Lisa Brauch ,&nbsp;Fiona Brunnert ,&nbsp;Ricarda Rauschenberg ,&nbsp;Andrea Forschner ,&nbsp;Xiomara Garza Vazquez ,&nbsp;Joanna Mangana ,&nbsp;Michael Erdmann ,&nbsp;Yenny Angela ,&nbsp;Cindy Franklin ,&nbsp;Julia Tietze ,&nbsp;Georg Lodde ,&nbsp;Alpaslan Tasdogan ,&nbsp;Johanna A. Seier ,&nbsp;Alexander Roesch ,&nbsp;Selma Ugurel ,&nbsp;Carola Berking ,&nbsp;Ralf Gutzmer ,&nbsp;Lisa Zimmer","doi":"10.1016/j.ejca.2026.116595","DOIUrl":"10.1016/j.ejca.2026.116595","url":null,"abstract":"<div><h3>Background</h3><div>Patients with advanced melanoma progressing after immune checkpoint inhibition (ICI) and BRAF/MEK inhibition have limited therapeutic options. In the LEAP-004 trial, pembrolizumab plus lenvatinib demonstrated activity in PD-1-refractory melanoma. The combination has emerged as a potential option when approved therapies have been exhausted; however, real-world evidence regarding its efficacy remains limited.</div></div><div><h3>Methods</h3><div>This retrospective, multicenter DeCOG study included patients with advanced melanoma treated with anti-PD-1 plus lenvatinib after failure of anti-PD-1-based therapy at 11 major skin-cancer centers in Germany and Switzerland between October 2020 and March 2025.</div></div><div><h3>Results</h3><div>Overall, 120 patients were analyzed (median age 59 years); 70 % were male and 38 % had an ECOG performance status &gt; 1. Most patients had ≥ 3 metastatic sites (69 %), brain metastases (42 %), and elevated LDH (58 %). Median follow-up was 13.4 months. Patients received a median of two prior systemic therapy lines; 98 % had been pretreated with ipilimumab/nivolumab, and 66 % exhibited primary resistance to prior ICI. The objective response rate was 23 %, with a median duration of response of 10 months; disease control rate was 47 %. Median progression-free survival (mPFS) was 4 months and median overall survival (mOS) was 10 months, with 12-month PFS and OS rates of 17 % and 42 %, respectively. Durable disease control beyond six months was observed in 23 % of patients, with mPFS of 21 months. Grade ≥ 3 treatment-related adverse events occurred in 21 % of patients.</div></div><div><h3>Conclusions</h3><div>In this real-world cohort, anti-PD-1 plus lenvatinib demonstrated meaningful efficacy in a subset of heavily pretreated patients, predominantly in those with BRAF wild-type melanoma.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116595"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147303781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreatic Diseases (EUROPAC)","authors":"Phillip J. Hopley ,&nbsp;Ryan Peysner ,&nbsp;Annabelle Boughey ,&nbsp;Bharti Kewlani ,&nbsp;Andrew M. Smith ,&nbsp;Guruprasad P. Aithal ,&nbsp;Kofi W. Oppong ,&nbsp;Meg Finch-Jones ,&nbsp;Zaed Hamady ,&nbsp;Tejinderjit S. Athwal ,&nbsp;James Milburn ,&nbsp;Shyam Menon ,&nbsp;Michael Chapman ,&nbsp;Stephen P. Pereira ,&nbsp;Mark Taylor ,&nbsp;Guy Shingler ,&nbsp;Christopher Briggs ,&nbsp;Paula Ghaneh ,&nbsp;Eithne Costello ,&nbsp;William Greenhalf ,&nbsp;Christopher M. Halloran","doi":"10.1016/j.ejca.2026.116592","DOIUrl":"10.1016/j.ejca.2026.116592","url":null,"abstract":"<div><h3>Background</h3><div>Surveillance of individuals with a familial predisposition to pancreatic ductal adenocarcinoma (PDAC) is likely to increase overall survival. Our objective was to determine the impact of EUROPAC risk-stratification (Family Risk, FR), in such predisposed individuals.</div></div><div><h3>Methods</h3><div>Observational study of registered asymptomatic individuals undergoing surveillance for PDAC. Individuals without a known pathogenic variant (PV-), ineligible for genetic assessment in the NHS, in whom significant pancreatic lesions were found, were subjected to additional germline testing.</div></div><div><h3>Results</h3><div>Between January 2000 and April 2025, 893 individuals started surveillance, median age of 52 years. 508 individuals (404 PV- and 104 with a pathogenic variant (PV+)) in the 20 years prior to 2020 without stratification were compared to 385 (269 PV- and 116 PV+) in the five years from 2020 who had FR risk-stratification applied. Four (0·8 %) individuals had actionable pancreatic findings prior to risk stratification vs. 14 (3·6 %), who underwent risk-stratified surveillance (<em>p</em> = 0·001). Pancreatic lesions deemed operable were found in three (0·6 %) and 11 (3 %), <em>p</em> = 0·007, with two (0·4 %) and nine (2 %) undergoing resection, <em>p</em> = 0·009, respectively. PV- individuals with significant findings were subsequently found to contain mutations, many not in the UK genetics test directory, provided the FR was &gt; 30. The median (IQR) time in surveillance prior to a lesion being detected was four (2 – 7) years. Overall, 78 % of EUROPAC detected precursor lesions or pancreatic cancers were stage II or lower.</div></div><div><h3>Conclusion</h3><div>The risk-stratified group (FR) identifies neoplastic pancreatic lesion in individuals, regardless of PV status suggesting the key usefulness of this approach.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116592"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147303813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}